Page last updated: 2024-08-21

arsenic trioxide and Pheochromocytoma, Extra-Adrenal

arsenic trioxide has been researched along with Pheochromocytoma, Extra-Adrenal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Carrasquillo, JA; Cheung, NK; Kramer, K; Kushner, BH; Larson, SM; Modak, S; Pandit-Taskar, N; Zanzonico, P	1

Trials

1 trial(s) available for arsenic trioxide and Pheochromocytoma, Extra-Adrenal

Article	Year
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:2 Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Male; Neuroblastoma; Oxides; Paraganglioma; Pheochromocytoma; Radiation-Sensitizing Agents; Radiopharmaceuticals; Survival Analysis; Treatment Outcome	2016

Article

Year

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:2

Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Male; Neuroblastoma; Oxides; Paraganglioma; Pheochromocytoma; Radiation-Sensitizing Agents; Radiopharmaceuticals; Survival Analysis; Treatment Outcome

2016